Revenue: As of FY2025, the actual value is USD 236.56 K.EPS: As of FY2025, the actual value is USD -0.05.EBIT: As of FY2025, the actual value is USD -128.11 K.<h3>Segment Revenue</h3><ul><li>Revenues: $126,560 for the fiscal year ended September 30, 2025, consistent with the previous year.</li><li>Revenues, Related Party: $110,001 for the fiscal year ended September 30, 2025, slightly up from $110,000 in the previous year.</li></ul><h3>Operational Metrics</h3><ul><li>Operating Expenses: Total operating expenses were $575,101 for the fiscal year ended September 30, 2025, down from $653,781 in the previous year, primarily due to a significant reduction in research and development expenses.</li><li>Research and Development: $11,725 for the fiscal year ended September 30, 2025, a substantial decrease from $153,685 in the previous year.</li><li>General and Administrative: $75,113 for the fiscal year ended September 30, 2025, up from $58,920 in the previous year.</li><li>Consulting and Professional Fees: $398,263 for the fiscal year ended September 30, 2025, up from $363,961 in the previous year.</li><li>Rent: $90,000 for the fiscal year ended September 30, 2025, up from $77,215 in the previous year.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $383,591 for the fiscal year ended September 30, 2025, compared to - $751,536 in the previous year, reflecting decreased operating expenses.</li><li>Net Cash Provided by Financing Activities: $452,430 for the fiscal year ended September 30, 2025, compared to $631,215 in the previous year, primarily from proceeds from notes payable and sale of common stock.</li></ul><h3>Unique Metrics</h3><ul><li>Derivative Income (Expense): - $675,528 for the fiscal year ended September 30, 2025, a significant increase from - $4,091 in the previous year, indicating a substantial derivative loss.</li></ul><h3>Outlook / Guidance</h3><ul><li>The company has incurred significant operating losses and negative cash flows from operations since inception, with an accumulated deficit of approximately $21 million as of September 30, 2025. The company is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities to continue operations.</li></ul>

Regen BioPharma, Inc. | 10-K: FY2025 Revenue: USD 236.56 K